Accelerate Diagnostics (NASDAQ:AXDX) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Accelerate Diagnostics (NASDAQ:AXDX) from a sell rating to a hold rating in a research note published on Thursday.

Accelerate Diagnostics Stock Performance

AXDX stock traded down $0.02 during trading on Thursday, hitting $1.85. The company had a trading volume of 25,482 shares, compared to its average volume of 82,394. Accelerate Diagnostics has a one year low of $0.73 and a one year high of $5.78. The business has a 50-day moving average of $1.77 and a 200-day moving average of $1.46.

Institutional Trading of Accelerate Diagnostics

A hedge fund recently raised its stake in Accelerate Diagnostics stock. Griffin Asset Management Inc. raised its stake in shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) by 1.9% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,380,654 shares of the medical research company’s stock after purchasing an additional 26,400 shares during the period. Griffin Asset Management Inc. owned 6.26% of Accelerate Diagnostics worth $1,615,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 17.14% of the company’s stock.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.